AtaiBeckley (NASDAQ:ATAI) shares reflect merger rights valued at 14% of par
NEW YORK, July 17, 2026, 07:07 EDT – Shares of AtaiBeckley (NASDAQ:ATAI) indicate a market valuation for merger rights amounting to 14% of their face value. AtaiBeckley Inc. (NASDAQ:ATAI) was priced…
Read the full articleYou might also wanna read
Lilly Announces $2.8 Billion Psychedelics Acquisition
The deal values AtaiBeckley at $6.75 per share, a 26% premium over its previous closing price
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
July 16 (Reuters) - AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedeli
Pharma giant Eli Lilly enters psychedelics space with AtaiBeckley takeover
AtaiBeckley stock rose more than 55% in after-hours trading Wednesday The post Pharma giant Eli Lilly enters psychedelics space with AtaiBec
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in the once-
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly said on Thursday it would buy AtaiBeckley for up to $3.8 billion, entering the race to develop psychedelic tre
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly said on Thursday it would buy AtaiBeckley for up to $3.8 billion, entering the race to develop psychedelic tre
Comments
Sign in to join the conversation.
No comments yet. Be the first.